Bosutinib resistance management

Bosutinib (Bosutinib) is an antineoplastic agent indicated for the treatment of adults with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who have failed to respond adequately to other treatments. If a patient develops resistance to bosutinib, genetic testing and molecular diagnostic technology can be used to determine the patient's specific mutation. Doctors may consider the following treatment methods.

Doctors can increase the dose of bosutinib to increase the concentration of the drug in the patient's body, thereby increasing its killing effect on cancer cells. Doctors may combine bosutinib with other leukemia drugs to make the treatment more effective. For example, combining it with other tyrosine kinase inhibitors or chemotherapy drugs. If resistance is severe, doctors may recommend stopping bosutinib and trying other treatment options, such as stem cell transplantation. Everyone’s constitution is different and their resistance to drugs is also different. If drug resistance develops after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of the Turkish version may be more than RMB 2,000 per box of 500mg*28, and the price of the European version may be more than RMB 30,000 (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.